FindTrial
Sign In

Combined Sevoflurane and Dexmedetomidine anesthesia attenuate myocardium injury and inflammatory responsevia P13K/Akt signaling pathway in coronary artery bypass grafting

Combined Sevoflurane and Dexmedetomidine anesthesia attenuate myocardium injury and inflammatory responsevia P13K/Akt signaling pathway in coronary artery bypass grafting

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900020924
Enrollment
Unknown
Registered
2019-01-22
Start date
2019-01-28
Completion date
Unknown
Last updated
2019-01-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

coronary artery bypass grafting

Interventions

control group:the same amount of0.9% saline as placebo
Sevoflurane group:Sevoflurane maintenance dose1.5MAC
Dexmedetomidine group:Dexmedetomidine maintenance dose 0.5µg/kg/h
combined group:Sevoflurane and Dexmedetomidine maintenance

Sponsors

The Second Affiliated Hospital of Jiaxing Medical College
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: 1. ASA class II-III; 2. CABG indications.

Exclusion criteria

Exclusion criteria: Combined with severe liver and kidney disease and cerebrovascular disease

Design outcomes

Primary

MeasureTime frame
cTnI;CK-MB;SOD;MDA;—

Countries

China

Contacts

Public ContactZhipeng Zhu

The Second Affiliated Hospital of Jiaxing Medical College

ljp200681@163.com+86 13967303968

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026